Transferrin-conjugated curcumin-loaded superparamagnetic iron oxide nanoparticles induce augmented cellular uptake and apoptosis in K562 cells

Acta Biomaterialia

Volumn 8, Issue 2, 2012, Pages 704-719

  Dilnawaz, Fahima ^a   Singh, Abhalaxmi ^a   Sahoo, Sanjeeb Kumar ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Apoptosis; Chronic myeloid leukemia; Magnetic field; Magnetic nanoparticles; Transferrin

Indexed keywords

CELL CULTURE; DISEASES; DRUG DELIVERY; IRON OXIDES; MAGNETIC FIELDS; METAL NANOPARTICLES; NANOMAGNETICS; SUPERPARAMAGNETISM;

ANTIPROLIFERATIVE ACTIVITIES; CELLULAR UPTAKE; CHRONIC MYELOID LEUKEMIAS; CONTRAST AGENT; CURCUMIN; IMAGE CONTRASTS; K562 CELLS; MAGNETIC-FIELD; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES; TRANSFERRIN;

CELL DEATH;

BCR ABL PROTEIN; CURCUMIN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRANSFERRIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG INDICATION; DRUG UPTAKE; HUMAN; HUMAN CELL; MAGNETIC FIELD; PRIORITY JOURNAL;

EID: 84855446953     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2011.10.022     Document Type: Article

References (64)

1. J. Bulte, T. Douglas, B. Witwer, S.-C. Zhang, E. Strable, and B.K. Lewis Nat Biotechnol 19 2001 1141
2. F. Dilnawaz, A. Singh, C. Mohanty, and S.K. Sahoo Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy Biomaterials 31 2010 3694
3. T. Jain, M. Morales, S.K. Sahoo, D. Leslie-Pelecky, and V. Labhasetwar Iron oxide nanoparticles for sustained delivery of anticancer agents Mol Pharm 194 2005
4. S. Prijic, J. Scancar, R. Romih, M. Cemazar, V. Bregar, and A. Znidarsic Increased cellular uptake of biocompatible superparamagnetic iron oxide nanoparticles into malignant cells by an external magnetic field J Membr Biol 236 2010 167
5. C. Alexiou, and R. Jurgons Magnetic drug targeting W. Andra, H. Nowak, Magnetism in Medicine: A Handbook 2007 Wiley-VCH Berlin 596
6. K. Widder, A. Senyei, and D. Ranney Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents Adv Pharmacol Chemother 16 1979 213
7. S. Goodwin, C. Peterson, C. Hob, and C. Bittner Targeting and retention of magnetic targeted carriers (MTCs) enhancing intraarterial chemotherapy J Magn Mater 194 1999 132
8. S. Pulfer, S. Ciccotto, and J. Gallo Distribution of small magnetic particles in brain tumor-bearing rats J Neuro Oncol 41 1999 99
9. C. Hüttinger, J. Hirschberger, A. Jahnke, R. Kostlin, T. Brill, and C. Plank J Gene Med 10 2008 655
10. A. Jahnke, J. Hirschberger, C. Fischer, T. Brill, R. Köstlin, and C. Plank Vet Med A Physiol Pathol Clin Med 54 2007 599
11. D. Leszczynski Rapporteur report: cellular, animal and epidemiological studies of the effects of static magnetic fields relevant to human health Prog Biophys Mol Biol 87 2004 247
12. M. Das, C. Mohanty, and S.K. Sahoo Ligand-based targeted therapy for cancer tissue Expert Opin Drug Delivery 6 2009 285
13. Z. Qian, H. Li, H. Sun, and K. Ho Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway Pharmacol Rev 54 2002
14. A. Widera, K.J.J. Kim, E.D. Crandall, and W.-C. Shen Transcytosis of GCSF-transferrin across rat alveolar epithelial cell monolayers Pharm Res 20 2003 1231
15. R.S. Mulik, J. Mönkkönen, R.O. Juvonen, K.R. Mahadik, and A.R. Paradkar Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitroanticancer activity by induction of apoptosis Int J Pharm 398 1-2 2010 190
16. S.K. Sahoo, W. Ma, and V. Labhasetwar Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer Int J Cancer 112 2004 335
17. A. Jacquel, M. Herrant, L. Legros, N. Belhacene, F. Luciano, and G. Pages FASEB J 17 2003 2160
18. M. Terme, C. Borg, F. Guilhot, C. Masurier, C. Flament, and E.F. Wagner Cancer Res 65 2005 6409
19. A. Garg, and B.B. Aggarwal Nuclear transcription factor-kappa B as a target for cancer drug development Leukemia 16 2002 1053
20. P. Lunghi, A. Costanzo, M. Levrero, and A. Bonati Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells Blood 104 2004 519
21. T. Stiewe, and B. Putzer Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 9 2002 237
22. A. Pluta, U. Nyman, B. Joseph, T. Robak, B. Zhivotovsky, and P. Smolewski The role of p73 in hematological malignancies Leukemia 20 2006 756
23. J. Benard, S. Douc-Rasy, and J. Ahomadegbe TP53 family members and human cancers Hum Mutat 21 2003 182 191 (Pubitemid 36292961)
24. B.B. Aggarwal, A. Kumar, and A. Bharti Anticancer potential of curcumin: preclinical and clinical studies Anticancer Res 23 2003 363
25. C. Mohanty, S. Acharya, A.K. Mohanty, F. Dilnawaz, and S.K. Sahoo Curcumin encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy Nanomed (Lond) 5 2010 433
26. W.L. Xian, X.J. Hua, W.G. Hua, and C.Y. Zhong Inhibitory effect of curcumin on proliferation of K562 cells involves down-regulation of p210bcr/abl-initiated Ras signal transduction pathway Acta Pharmacol Sin 24 2003 1155
27. P. Limtrakul, W. Chearwae, S. Shukla, C. Phisalphong, and S.V. Ambudkar Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin Mol Cell Biochem 296 2007 85
28. R. Misra, and S.K. Sahoo Co-formulation of doxorubicin and curcumin in poly (d,l-lactide-co-glycolide) nanoparticles suppress the development of multi drug resistance in K562 cells Mol Pharm 8 2011 852
29. J. Jaetao, K. Butler, N. Adolphi, D. Lovato, H. Bryant, and I. Rabinowitz Cancer Res 69 2009 8310
30. R. Konwarh, J.P. Saikia, N. Karak, and B.K. Konwar Poly(ethylene glycol)-magnetic nanoparticles-curcumin' trio: directed morphogenesis and synergistic free-radical scavenging Colloids Surf B Biointerfaces 81 2010 578
31. M.M. Yallapu, S.F. Othman, E.T. Curtis, B.K. Gupta, M. Jaggi, and S.C. Chauhan Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy Biomaterials 32 2011 1890
32. G. Zhang, B.B. Lai, Y.Y. Zhou, B.A. Chen, X.M. Wang, and Q. Lu Nanomed Nanotechnol Biol Med 1 2011
33. B. Chen, Y. Liang, W. Wu, J. Cheng, G. Xia, and F. Gao Int J Nanomed 4 2009 251
34. G. Lv, F. He, X. Wang, F. Gao, G. Zhang, and T. Wang Langmuir 24 2008 2151
35. R. Misra, and S.K. Sahoo Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy Eur J Pharm Sci 39 2010 152
36. J. Shaikh, D.D. Ankola, V. Beniwal, D. Singh, and M.N.V. Ravi Kumar Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer Eur Pharm Sci 37 2009 223
37. A. Singh, F. Dilnawaz, S. Mewar, U. Sharma, N.R. Jagannathan, and S.K. Sahoo Composite polymeric magnetic nanoparticles for co-delivery of hydrophobic and hydrophilic anticancer drugs and MRI imaging for cancer therapy ACS Appl Mater Interfaces 3 2011 846
38. X. Li, L. Ding, Y. Xu, Y. Wang, and Q. Ping Targeted delivery of doxorubicin using stealth liposomes modified with transferrin Int J Pharm 373 2009 116
39. S. Acharya, F. Dilnawaz, and S.K. Sahoo Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy Biomaterials 30 2009 5737
40. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 1983 55
41. C.D. Bortner, and J. Cidlowski Caspase independent/dependent regulation of K(+), cell shrinkage, and mitochondrial membrane potential during lymphocyte apoptosis J Biol Chem 274 1999 21953
42. A. Cossarizza, M. Baccarani-Contri, G. Kalashnikova, and C. Franceschi A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,50,6,60-tetrachloro-1,10,3, 30-tetraethylbenzimidazolcarbocyanine iodide (JC-1) Biochem Biophys Res Commun 197 1993
43. R. Misra, S. Acharya, F. Dilnawaz, and S.K. Sahoo Sustained antibacterial activity of doxycycline-loaded poly(d,l-lactide-co-glycolide) and poly(epsilon-caprolactone) nanoparticles Nanomed (Lond) 4 2009 519
44. B. Zebib, Z. Mouloungui, and V. Noirot Stabilization of curcumin by complexation with divalent cations in glycerol/water system Bioinorg Chem Appl 1 2010
45. D. Luo, and W. Saltzman Enhancement of transfection by physical concentration of DNA at the cell surface Nat Biotechnol 18 2000 893
46. J. Wang, S. Tian, R.A. Petros, M.E. Napier, and J.M. DeSimone The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies J Am Chem Soc 132 2010 11306
47. M. Vandana, and S.K. Sahoo Optimization of physicochemical parameters influencing the fabrication of protein-loaded chitosan nanoparticles Nanomed (Lond) 4 2009 773
48. S. Wong, and O. Witte The BCR-ABL story: bench to bedside and back Annu Rev Immunol 22 2004 247
49. U. Peters, M. Tschan, and K. Kreuzer Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transenptionpolymerase chain reaction assay and protein analysis Cancer Res 59 1999 4233
50. U. Novak, T. Grob, G. Baskaynak, U. Peters, S. Aebi, and D. Zwahlen Ann Oncol 12 2001 981
51. D. Altieri Validating survivin as a cancer therapeutic target Nat Rev Cancer 3 2003 46
52. 4 nanoparticles in vitro J Mater Sci Mater Med 18 2007 2145
53. C. Yu, J. Zhao, Y. Guo, C. Lu, X. Ma, and Z. Gu A novel method to prepare waterdispersible magnetic nanoparticles and their biomedical applications: magnetic capture probe and specific cellular uptake J Biomed Mater Res A 87 2008 364
54. M. Sincai, L. Deleanu, D. Argherie, and D. Bica The effects of magnetic fluids on blood parameters in dogs J Magn Magn Mater 252 2002 406
55. G. Sa, T. Das, S. Banerjee, and J. Chakraborty Curcumin: from exotic spice to modern anticancer drug Al Ameen J Med Sci 3 2010 21
56. S. Salvioli, E. Sikora, E. Cooper, and C. Franceschi Curcumin in cell death processes: a challenge for CAM of age-related pathologies Evid Based Complement Altern Med 4 2007 181
57. J. Kerr, C. Witerford, and B. Harmon Apoptosis: its significance in cancer and cancer therapy Cancer Lett 73 1994 2013
58. E. Laurent, M. Talpaz, H. Kantarjian, and R. Kurzrock The BCR gene and Philadelphia chromosome-positive leukemogenesis Cancer Res 61 2001 2343
59. L.X. Wu, J.H. Xu, G.H. Wu, and Y.Z. Chen Inhibitory effect of curcumin on proliferation of K562 cells involves down-regulation of p210(bcr/abl) initiated Ras signal transduction pathway Acta Pharmacol Sin 24 2003 1155
60. W. Toh, S. Nam, and K. Sabapathy An essential role for p73 in regulating mitotic cell death Cell Death Differ 17 2010 787
61. R. Ralhan, M. Pandey, and B. Aggarwal Nuclear factor-kappa B links carcinogenic and chemopreventive agents Front Biosci S1 2009 45
62. E. Zandi, and M. Karin Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex Mol Cell Biol 19 1999 4547
63. D. Altieri Survivin, versatile modulation of cell division and apoptosis in cancer Oncogene 22 2003 8581
64. K. Wolanin, A. Magalska, G. Mosieniak, R. Klinger, S. McKenna, and S. Vejda Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells Mol Cancer Res 4 2006 457